A recently published study on the use of somatostatin when the retrograde cholangiopancreatography (ERCP) demonstrated its effectiveness in reducing the likelihood of developing pancreatitis. In this work, somatostatin used either as a continuous 12-hour infusion, starting 30 minutes prior to the ERCP, or as a bolus intravenous injection at the time of cannulation of large duodenal papilla. Percentage of pancreatitis in both groups was 1.7%, whereas in the placebo group it reached 9.8%. What design of the study was conducted